IDEAYA Biosciences, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Quarterly earnings show how the company performed and whether it's on track with investor expectations.
Shareholders vote on company leadership and major decisions that affect your investment's future direction.
Company raises cash but increases total shares outstanding, which can dilute existing shareholders' ownership.
Partnership with a major pharmaceutical company validates the company's drug candidate and could lead to future revenue.
Stocky reads IDEAYA Biosciences, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
IDEAYA Biosciences, Inc.'s most recent tracked filing was a 10-Q on 4 Aug 2026: Reports second quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.